The minimum element of a synthetic peptide required to block prostate tumor cell migration

Cancer Biology and Therapy

Volumn 5, Issue 11, 2006, Pages 1556-1562

  Sroka, Thomas C ^a,b   Marik, Jan ^c   Pennington, Michael E ^a   Lam, Kit S ^c   Cress, Anne E ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell adhesion; ERK signaling; Migration; Prostate cancer; Synthetic peptide

Indexed keywords

LYSYLISOLEUCYLLYSYLMETHIONYLVALYLISOLEUCYLSERYLTRYPTOPHYLLYSYLGLYCINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER;

EID: 33846958061     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.11.3461     Document Type: Article

References (53)

1. Chambers AF, MacDonald IC, Schmidt EE, Morris VL, Groom AC. Clinical targets for anti-metastasis therapy. Adv Cancer Res 2000; 79:91-121.
2. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2:563-72.
3. Kawaguchi T. Cancer metastasis: Characterization and identification of the behavior of metastatic tumor cells and the cell adhesion molecules, including carbohydrates. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5:39-64.
4. Okegawa T, Pong RC, Li Y, Hsieh JT. The role of cell adhesion molecule in cancer progression and its application in cancer therapy. Acta Biochim Pol 2004; 51:445-57.
5. Jin H, Varner J. Integrins: Roles in cancer development and as treatment targets. Br J Cancer 2004; 90:561-5.
6. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002; 2:91-100.
7. Hynes RO. Integrins: Bidirectional, allosteric signaling machines. Cell 2002; 110:673-87.
8. Cress AE, Rabinovitz I, Zhu W, Nagle RB. The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cancer Metastasis Rev 1995; 14:219-28.
9. Friedrichs K, Ruiz P, Franke F, Gille I, Terpe HJ, Imhof BA. High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res 1995; 55:901-6.
10. Rosendahl A, Neumann K, Chaloupka B, Rothmund M, Weinel RJ. Expression and distribution of VLA receptors in the pancreas: An immunohistochemical study. Pancreas 1993; 8:711-8.
11. Hibino S, Shibuya M, Engbring JA, Mochizuki M, Nomizu M, Kleinman HK. Identification of an active site on the laminin alpha5 chain globular domain that binds to CD44 and inhibits malignancy. Cancer Res 2004; 64:4810-6.
12. Ponce ML, Hibino S, Lebioda AM, Mochizuki M, Nomizu M, Kleinman HK. Identification of a potent peptide antagonist to an active laminin-1 sequence that blocks angiogenesis and tumor growth. Cancer Res 2003; 63:5060-4.
13. Nomizu M, Kim WH, Yamamura K, Utani A, Song SY, Otaka A, Roller PP, Kleinman HK, Yamada Y. Identification of cell binding sites in the laminin alpha 1 chain carboxyl-terminal globular domain by systematic screening of synthetic peptides. J Biol Chem 1995; 270:20583-90.
14. Nakahara H, Mueller SC, Nomizu M, Yamada Y, Yeh Y, Chen WT. Activation of beta1 integrin signaling stimulates tyrosine phosphorylation of p190RhoGAP and membrane-protrusive activities at invadopodia. J Biol Chem 1998; 273:9-12.
15. Bresalier RS, Schwartz B, Kim YS, Duh QY, Kleinman HK, Sullam PM. The laminin alpha 1 chain Ile-Lys-Val-Ala-Val (IKVAV)-containing peptide promotes liver colonization by human colon cancer cells. Cancer Res 1995; 55:2476-80.
16. Skubitz AP, Letourneau PC, Wayner E, Furcht LT. Synthetic peptides from the carboxy-terminal globular domain of the A chain of laminin: Their ability to promote cell adhesion and neurite outgrowth, and interact with heparin and the beta 1 integrin subunit. J Cell Biol 1991; 115:1137-48.
17. Song SY, Nomizu M, Yamada Y, Kleinman HK. Liver metastasis formation by laminin-1 peptide (LQVQLSIR)-adhesion selected B16-F10 melanoma cells. Int J Cancer 1997; 71:436-41.
18. Iwamoto Y, Robey FA, Graf J, Sasaki M, Kleinman HK, Yamada Y, Martin GR. YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 1987; 238:1132-4.
19. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984; 309:30-3.
20. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238:491-7.
21. Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 1986; 233:467-70.
22. Gehlsen KR, Argraves WS, Pierschbacher MD, Ruoslahti E. Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides. J Cell Biol 1988; 106:925-30.
23. Engbring JA, Kleinman HK. The basement membrane matrix in malignancy. J Pathol 2003; 200:465-70.
24. Lam KS, Salmon SE, Hersh EM, Hruby VJ, Kazmierski WM, Knapp RJ. A new type of synthetic peptide library for identifying ligand-binding activity. Nature 1991; 354:82-4.
25. Lam KS, Lebl M, Krchnak V. The "one-bead-one-compound" combinatorial library method. Chem Rev 1997; 97:411-48.
26. Lam KS, Liu R, Miyamoto S, Lehman AL, Tuscano JM. Applications of one-bead one-compound combinatorial libraries and chemical microarrays in signal transduction research. Acc Chem Res 2003; 36:370-7.
27. Cwirla SE, Peters EA, Barrett RW, Dower WJ. Peptides on phage: A vast library of peptides for identifying ligands. Proc Natl Acad Sci USA 1990; 87:6378-82.
28. Devlin JJ, Panganiban LC, Devlin PE. Random peptide libraries: A source of specific protein binding molecules. Science 1990; 249:404-6.
29. Rodi DJ, Makowski L, Kay BK. One from column A and two from column B: The benefits of phage display in molecular-recognition studies. Curr Opin Chem Biol 2002; 6:92-6.
30. Aina OH, Sroka TC, Chen ML, Lam KS. Therapeutic cancer targeting peptides. Biopolymers 2002; 66:184-99.
31. Pennington ME, Lam KS, Cress AE. The use of a combinatorial library method to isolate human tumor cell adhesion peptides. Mol Divers 1996; 2:19-28.
32. DeRoock IB, Pennington ME, Sroka TC, Lam KS, Bowden GT, Bair EL, Cress AE. Synthetic peptides inhibit adhesion of human tumor cells to extracellular matrix proteins. Cancer Res 2001; 61:3308-13.
33. Sroka TC, Pennington ME, Cress AE. Synthetic D-amino acid peptide inhibits tumor cell motility on laminin-5. Carcinogenesis 2006; 27:1748-57.
34. Tran NL, Nagle RB, Cress AE, Heimark RL. N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion with Stromal cells. Am J Pathol 1999; 155:787-98.
35. Breitkreutz D, Schoop VM, Mirancea N, Baur M, Stark HJ, Fusenig NE. Epidermal differentiation and basement membrane formation by HaCaT cells in surface transplants. Eur J Cell Biol 1998; 75:273-86.
36. Song A, Wang X, Zhang J, Marik J, Lebrilla CB, Lam KS. Synthesis of hydrophilic and flexible linkers for peptide derivatization in solid phase. Bioorg Med Chem Lett 2004; 14:161-5.
37. Grieco P, Gitu PM, Hruby VJ. Preparation of 'side-chain-to-side-chain' cyclic peptides by Allyl and Alloc strategy: Potential for library synthesis. J Pept Res 2001; 57:250-6.
38. Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem 1970; 34:595-8.
39. Kerr JS, Slee AM, Mousa SA. The alpha v integrin antagonists as novel anticancer agents: An update. Expert Opin Investig Drugs 2002; 11:1765-74.
40. Tucker GC. Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 2003; 4:722-31.
41. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA. Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000; 6:3056-61.
42. Mikecz K. Vitaxin applied molecular evolution. Curr Opin Investig Drugs 2000; 1:199-203.
43. Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, Benjamin RS. Pilot study of vitaxin-an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer 2001; 92:1347-8.
44. Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, LoBuglio AF. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001; 16:125-32.
45. Smith JW. Cilengitide merck. Curr Opin Investig Drugs 2003; 4:741-5.
46. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 2003; 39:917-26.
47. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002; 62:4263-72.
48. Raguse JD, Gath HJ, Bier J, Riess H, Oettle H. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol 2004; 40:228-30.
49. Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, Bucana CD, Gallick GE, Nickols MA, Westlin WF, Ellis LM. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res 2003; 63:2079-87.
50. Carey TE, Laurikainen L, Ptok A, Reinke T, Linder K, Nair TS, Marcelo C. Culture conditions affect expression of the alpha 6 beta 4 integrin associated with aggressive behavior in head and neck cancer. Adv Exp Med Biol 1992; 320:69-79.
51. Rabinovitz I, Mercurio AM. The integrin alpha 6 beta 4 and the biology of carcinoma. Biochem Cell Biol 1996; 74:811-21.
52. Weinel RJ, Rosendahl A, Neumann K, Chaloupka B, Erb D, Rothmund M, Santoso S. Expression and function of VLA-alpha 2, -alpha 3, -alpha 5 and -alpha 6-integrin receptors in pancreatic carcinoma. Int J Cancer 1992; 52:827-33.
53. Li P, Liu R, Marik J, Wang W, Takada Y, Lam KS. Identification of high-affinity peptidomimetics against a4b1 integrin using combinatorial chemistry. Nature Chemical Biology 2006; 2:381-9.